193 related articles for article (PubMed ID: 8998950)
1. Incorporating Monte Carlo simulation into physiologically based pharmacokinetic models using advanced continuous simulation language (ACSL): a computational method.
Thomas RS; Lytle WE; Keefe TJ; Constan AA; Yang RS
Fundam Appl Toxicol; 1996 May; 31(1):19-28. PubMed ID: 8998950
[TBL] [Abstract][Full Text] [Related]
2. Reassessing benzene risks using internal doses and Monte-Carlo uncertainty analysis.
Cox LA
Environ Health Perspect; 1996 Dec; 104 Suppl 6(Suppl 6):1413-29. PubMed ID: 9118928
[TBL] [Abstract][Full Text] [Related]
3. A trichloroethylene risk assessment using a Monte Carlo analysis of parameter uncertainty in conjunction with physiologically-based pharmacokinetic modeling.
Cronin WJ; Oswald EJ; Shelley ML; Fisher JW; Flemming CD
Risk Anal; 1995 Oct; 15(5):555-65. PubMed ID: 7501875
[TBL] [Abstract][Full Text] [Related]
4. Structure and parameterization of pharmacokinetic models: their impact on model predictions.
Woodruff TJ; Bois FY; Auslander D; Spear RC
Risk Anal; 1992 Jun; 12(2):189-201. PubMed ID: 1502372
[TBL] [Abstract][Full Text] [Related]
5. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.
Krauss M; Tappe K; Schuppert A; Kuepfer L; Goerlitz L
PLoS One; 2015; 10(10):e0139423. PubMed ID: 26431198
[TBL] [Abstract][Full Text] [Related]
6. Physiologically-based pharmacokinetic modeling of benzene in humans: a Bayesian approach.
Yokley K; Tran HT; Pekari K; Rappaport S; Riihimaki V; Rothman N; Waidyanatha S; Schlosser PM
Risk Anal; 2006 Aug; 26(4):925-43. PubMed ID: 16948686
[TBL] [Abstract][Full Text] [Related]
7. Development of a human physiologically based pharmacokinetic (PBPK) model for phthalate (DEHP) and its metabolites: A bottom up modeling approach.
Sharma RP; Schuhmacher M; Kumar V
Toxicol Lett; 2018 Oct; 296():152-162. PubMed ID: 29958929
[TBL] [Abstract][Full Text] [Related]
8. Estimation of interindividual pharmacokinetic variability factor for inhaled volatile organic chemicals using a probability-bounds approach.
Nong A; Krishnan K
Regul Toxicol Pharmacol; 2007 Jun; 48(1):93-101. PubMed ID: 17367907
[TBL] [Abstract][Full Text] [Related]
9. Uncertainty, variability, and sensitivity analysis in physiological pharmacokinetic models.
Krewski D; Wang Y; Bartlett S; Krishnan K
J Biopharm Stat; 1995 Nov; 5(3):245-71. PubMed ID: 8580927
[TBL] [Abstract][Full Text] [Related]
10. Assessing drug distribution in tissues expressing P-glycoprotein using physiologically based pharmacokinetic modeling: identification of important model parameters through global sensitivity analysis.
Fenneteau F; Li J; Nekka F
J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):495-522. PubMed ID: 19847628
[TBL] [Abstract][Full Text] [Related]
11. Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data.
Wendling T; Tsamandouras N; Dumitras S; Pigeolet E; Ogungbenro K; Aarons L
AAPS J; 2016 Jan; 18(1):196-209. PubMed ID: 26538125
[TBL] [Abstract][Full Text] [Related]
12. Modeling benzene pharmacokinetics across three sets of animal data: parametric sensitivity and risk implications.
Spear RC; Bois FY; Woodruff T; Auslander D; Parker J; Selvin S
Risk Anal; 1991 Dec; 11(4):641-54. PubMed ID: 1780503
[TBL] [Abstract][Full Text] [Related]
13. Use of Markov Chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age.
Allen BC; Hack CE; Clewell HJ
Risk Anal; 2007 Aug; 27(4):947-59. PubMed ID: 17958503
[TBL] [Abstract][Full Text] [Related]
14. A fuzzy physiologically based pharmacokinetic modeling framework to predict drug disposition in humans.
Seng KY; Vicini P; Nestorov IA
Conf Proc IEEE Eng Med Biol Soc; 2006; 2006():5037-40. PubMed ID: 17947127
[TBL] [Abstract][Full Text] [Related]
15. Variability of physiologically based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene (PCE).
Gearhart JM; Mahle DA; Greene RJ; Seckel CS; Flemming CD; Fisher JW; Clewell HJ
Toxicol Lett; 1993 May; 68(1-2):131-44. PubMed ID: 8516760
[TBL] [Abstract][Full Text] [Related]
16. A methodology for solving physiologically based pharmacokinetic models without the use of simulation softwares.
Haddad S; Pelekis M; Krishnan K
Toxicol Lett; 1996 May; 85(2):113-26. PubMed ID: 8650694
[TBL] [Abstract][Full Text] [Related]
17. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
18. Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans.
El-Masri HA; Bell DA; Portier CJ
Toxicol Appl Pharmacol; 1999 Aug; 158(3):221-30. PubMed ID: 10438655
[TBL] [Abstract][Full Text] [Related]
19. Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects.
Jonsson F; Bois FY; Johanson G
Arch Toxicol; 2001 Jun; 75(4):189-99. PubMed ID: 11482516
[TBL] [Abstract][Full Text] [Related]
20. Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation.
Thomas RS; Bigelow PL; Keefe TJ; Yang RS
Am Ind Hyg Assoc J; 1996 Jan; 57(1):23-32. PubMed ID: 8588550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
